References
- Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
- Bignami M, O’Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat. Res.462(2–3), 71–82 (2000).
- Dumenco LL, Warman B, Hatzoglou M, Lim IK, Abboud SL, Gerson SL. Increase in nitrosourea resistance in mammalian cells by retrovirally mediated gene transfer of bacterial O6-alkylguanine-DNA alkyltransferase. Cancer Res.49(21), 6044–6051 (1989).
- Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
- Gilbert MR, Wang M, Aldape KD et al. RTOG 0525: a randomized Phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts29(Suppl. 15), 2006 (2011).
- Aldape KD, Wang M, Sulman EP et al. RTOG 0525: molecular correlates from randomized Phase III trial of newly diagnosed glioblastoma (GBM). ASCO Meeting Abstracts29(Suppl. 15), LBA2000 (2011).
- Tabatabai G, Frank B, Wick A et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann. Neurol.61(2), 153–161 (2007).
- Wick W, Steinbach J, Combs SE et al. Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled Phase II study. ASCO Meeting Abstracts29(Suppl. 15), 2007 (2011).
- Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan–Kettering Cancer Center prognostic model. J. Clin. Oncol.24(36), 5711–5715 (2006).
- Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a Phase 3, randomised, non-inferiority trial. Lancet Oncol.11(11), 1036–1047 (2010).
- Jahnke K, Korfel A, Martus P et al. Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized Phase III trial (G-PCNSL-SG-1). ASCO Meeting Abstracts29(Suppl. 15), 2004 (2011).
- Martus P, Jahnke K, Korfel A et al. Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: results from a German Phase III trial (G-PCNSL-SG-1). ASCO Meeting Abstracts29(Suppl. 15), 2005 (2011).
- CBTRUS. 1995–1999 Statistical Report: primary brain tumors in the United States. In: Central Brain Tumor Registry of the United States. CBTRUS, IL, USA (2002).
- Packer RJ, Gajjar A, Vezina G et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol.24(25), 4202–4208 (2006).
- Dhall G, Grodman H, Ji L et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the ‘Head Start’ I and II protocols. Pediatr. Blood Cancer50(6), 1169–1175 (2008).
- Dhall G, Ji L, Haley K et al. Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol. ASCO Meeting Abstracts29(Suppl. 15), (2011) Abstract 2011.
Websites
- Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiforme http://clinicaltrials.gov/ct2/show/NCT00977431?term=unmethylated+glioblastoma&rank=4
- Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status (CORE) http://clinicaltrials.gov/ct2/show/NCT00813943?term=NCT00813943&rank=1